Beneath these individual signals, a single structural reality is hardening: the regulatory apparatus is not blocking psychedelic medicine — it is building around it. What looks like friction from the outside is, at a deeper level, scaffolding. The FDA's anticipated cardiac screening requirements for ibogaine are not a wall but a channel — a framework that, once established, actually enables supervised veteran access inside DoD settings without requiring Schedule I rescheduling. The SSRI washout guidance, when it arrives, will narrow trial variability and sharpen outcome data in ways that ultimately strengthen every future NDA. The DEA's anticipated opposition to NDAA ibogaine provisions will likely trigger a DOJ General Counsel opinion — a procedural escalation that, paradoxically, forces the question into formal federal deliberation rather than legislative ambiguity. The highest trajectory available from this moment is not a sudden opening but a structured one: safety floors being poured, access channels being carved, the field being forced toward the precision that durable approval requires.
The real people inside today's signals are veterans — men and women carrying treatment-resistant PTSD and opioid dependence who have, in some cases, traveled to clinics in Mexico or Costa Rica because no sanctioned domestic pathway exists. For them, every month of regulatory deliberation is not abstract. It is another month of interrupted sleep, fractured relationships, the particular exhaustion of a nervous system that cannot fully return from where it has been. What is genuinely forming for them is a staged access framework — supervised, cardiac-monitored, DoD-adjacent — that could reach them within 18 to 24 months without requiring Congress to move. That is not everything they need. But it is real, and it is closer than it has ever been. The SSRI washout guidance, when it arrives, will also quietly benefit the patients enrolled in psilocybin trials who have been on antidepressants for years — not sidelining them, but giving researchers the clean signal that will make the evidence for their treatment unimpeachable.
Every authentic ceremony is a reclamation — of the body, the breath, the forgotten self. OOTW exists to hold space for that reclamation as the science arrives to name it.
Every thread you follow today was laid by a hand that knew you were coming.
90%
Congress won't pass a standalone psychedelic bill before mid-2026
Right now, Congress has no psychedelic scheduling bills scheduled for a real hearing. The DEA (Drug Enforcement Administration) opposes them. With fewer than 15 weeks of actual legislative time left before the November 2026 elections, a standalone bill has almost no chance—the only realistic path would be sneaking it into a larger military spending bill or budget bill.
→ Congress won't pass a standalone psychedelic scheduling bill before November 2026; any change must piggyback on military or budget legislation.
Resolves: 2026-11-03 · USA
LEGISLATION
the precise call ▾
No standalone federal psychedelic scheduling bill will pass both chambers before the 2026 midterms.. Standalone psychedelic scheduling bills have no committee hearing scheduled, face DEA opposition, and the congressional calendar leaves fewer than 15 legislative weeks before November 2026. NDAA or appropriations riders remain the only plausible vehicles. The duplicate prediction (#3) is removed; th
78%
Two more states will propose veteran psychedelic therapy access laws in 2026
States like Texas, Colorado, Oregon, and Arizona are already moving ahead with their own psychedelic therapy programs—they don't wait for the federal government. By the end of 2026, at least two additional states will formally introduce (file) new bills creating veteran-only psychedelic therapy programs. This counts bills filed, even if they don't pass, because state-level momentum is real and separate from federal drug scheduling.
→ At least two new states will introduce veteran-specific psychedelic therapy bills in 2026, continuing momentum independent of federal law.
Resolves: 2026-12-31 · USA
LEGISLATION
the precise call ▾
At least two additional U.S. states will formally introduce legislation establishing veteran-specific psychedelic therapy access programs in calendar year 2026.. State legislative momentum is documented and decoupled from federal scheduling for ketamine and advancing for psilocybin. 'Introduce' (bill filing) is a low but falsifiable bar. Confidence is reasonable given existing state-level activity in TX, CO, OR, and AZ. Slightly trimmed from 0.81 because 'in
72%
DEA will formally oppose any law letting veterans skip ibogaine review
Some in Congress want to create a fast track for military veterans to access ibogaine without waiting for Schedule I review (the formal drug classification process). The DEA has legal standing and institutional reasons to block this—they will write an official letter or Congressional statement opposing any law that lets ibogaine bypass the normal review process.
→ The DEA will officially oppose any congressional law that lets veterans use ibogaine without going through the normal Schedule I review process.
Resolves: 2026-12-31 · USA
LEGISLATION
the precise call ▾
DEA will submit formal written opposition to any NDAA provision creating ibogaine veteran access that bypasses Schedule I review, before December 31 2026.. DEA has institutional incentive and procedural standing to oppose Schedule I bypass via NDAA. The DOJ GC opinion request sub-claim is speculative and unfalsifiable without a document trail; it is removed. Resolved by existence of a public DEA letter, Congressional Record statement, or documented DOJ
62%
FDA will require heart screening before testing ibogaine in humans
Ibogaine (a plant-derived drug being tested for addiction) can damage the heart in serious ways—the data is public and clear. The FDA (US drug regulator) will almost certainly demand that any company testing ibogaine in humans first does heart screening tests (an ECG baseline and QTc measurement) before those humans start the drug. This protects patients and shields the FDA from liability.
→ The FDA will require heart screening tests for anyone in an ibogaine study before they receive the drug, because the cardiac risk is too well documented to ignore.
Resolves: 2026-12-31 · USA
REGULATION
the precise call ▾
FDA will issue formal written guidance requiring mandatory cardiac screening (ECG, QTc baseline) for any ibogaine IND submitted or amended in 2026.. Published QT prolongation and cardiovascular fatality data create a clear evidentiary record FDA cannot ignore without liability exposure. Formal written guidance—distinct from informal reviewer feedback—is the measurable bar here. A full REMS designation is unlikely this fast; the prediction is nar
57%
Ibogaine companies will publicly switch to safer chemical alternatives
Ibogaine works for some addictions but harms the heart. Companies and researchers testing ibogaine know this. By November 2026, at least one major company or academic lab will publicly announce they're shifting their main focus to safer versions—like oxa-noribogaine, a chemical cousin without the heart damage. They'll say this out loud in a press release or research announcement because the cardiac risk makes ibogaine hard to sell to regulators and patients.
→ At least one major ibogaine program will announce a public shift to safer chemical alternatives because heart damage is too big a liability.
Resolves: 2026-11-05 · Global
RESEARCH
the precise call ▾
By November 2026, at least one major ibogaine clinical-stage company or academic program will publicly announce a pivot toward non-cardiotoxic ibogaine analogs (e.g., oxa-noribogaine) as their primary development candidate.. Original prediction ('functionally redirect primary development') was too vague and unmeasurable. Sharpened to a falsifiable corporate or institutional announcement. Cardiac risk data is a genuine commercial and regulatory forcing function. 18-month window from today reaches November 2026. Confidenc